Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01678222 · ClinicalTrials.gov registry record
The COX-2 Gene and the Immune System
A clinical trial, sponsored by National Institute of Environmental Health Sciences (NIEHS).
- Completed
- Registry status
- 117
- Enrollment target
NCT01678222: Completed study, sponsored by National Institute of Environmental Health Sciences (NIEHS).
NCT01678222 is a clinical trial that has completed, run by National Institute of Environmental Health Sciences (NIEHS). The registered enrollment target is 117 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01678222 has completed, sponsored by National Institute of Environmental Health Sciences (NIEHS).
- COMPLETED
- Registry status
- 117 participants
- Enrollment target
Study Summary
Background: \- The immune system contains several different types of cells in the blood and other parts of the body. The body can fight infections well with the right balance of these cell types. The wrong balance of cell types may cause diseases, such as allergies or asthma. The COX-2 gene may help decide the balance of cell types that the body makes as part of the immune system. It may also play a role in certain immune system diseases. Researchers want to see how COX-2 affects the cells in the immune system. Objectives: \- To study how the COX-2 gene works in the body s immune system. Eligibility: \- Individuals 18 years of age and above who are part of the Environmental Polymorphisms Registry. Design: * Participants will have one study visit at the National Institutes of Health. They will collect a urine sample at home on the morning of the study visit. * Participants will have a physical exam and medical history. They will provide a blood sample. They will also give researchers the urine sample they collected that morning. * No treatment will be provided as part of this study.
Primary Outcome
To determine whether 765\>C is associated with altered Th2, Th9, and Th17 differentiation in vivo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2013-05-02 |
What the finished NCT01678222 record still lists
NCT01678222 is an observational study that tracks outcomes without assigning an intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01678222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01678222 about?
NCT01678222 is a clinical study titled "The COX-2 Gene and the Immune System". Background: \- The immune system contains several different types of cells in the blood and other parts of the body. The body can fight infections well with the right balance of these cell types. The wrong balance of cell types may cause diseases, such as allergies or asthma. The COX-2 gene may hel...
What is the current status of trial NCT01678222?
This trial is currently completed. The enrollment target is 117 participants. The study started on 2013-05-02.
Who is sponsoring clinical trial NCT01678222?
This trial is sponsored by National Institute of Environmental Health Sciences (NIEHS), which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI